Are Short-Sellers Right About Inovio?
Inovio Pharmaceuticals (NASDAQ: INO) started the coronavirus vaccine race on the right foot. Investors cheered last spring when the company became one of the first to bring a coronavirus vaccine candidate into human trials. And then Inovio lost steam. Some investors were disappointed by a lack of detail in the phase 1 clinical trial report. Later in the year, the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on its phase 2/3 trial.
Inovio is no longer a leader from a timeline perspective. Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have brought vaccines to market. And Johnson & Johnson (NYSE: JNJ) and Novavax (NASDAQ: NVAX) are requesting regulatory authorization. Meanwhile, short-sellers are betting that shares of Inovio -- up more than 56% since the start of the year -- are going to fall. Are they right?
Image source: Getty Images
Source Fool.com
